Maze Therapeutics, Inc.
MAZE
$14.28
$0.977.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -120.80M | 51.94M | 52.23M | 55.23M | 55.24M |
| Total Depreciation and Amortization | 2.83M | 3.03M | 3.30M | 3.57M | 3.78M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.41M | 18.10M | 21.95M | 23.76M | 20.58M |
| Change in Net Operating Assets | -6.66M | -3.20M | -1.52M | -4.80M | 1.39M |
| Cash from Operations | -105.23M | 69.88M | 75.95M | 77.76M | 81.00M |
| Capital Expenditure | -1.40M | -1.17M | -1.15M | -576.00K | -470.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.40M | -1.17M | -1.15M | -576.00K | -470.00K |
| Total Debt Issued | 0.00 | 259.00K | 24.48M | 40.65M | 40.65M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 128.78M | 128.25M | 733.00K | 682.00K | 464.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 70.79M | 70.79M | 70.79M | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.47M | -3.65M | -3.15M | -2.56M | -184.00K |
| Cash from Financing | 196.10M | 195.64M | 92.85M | 38.77M | 40.93M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.48M | 264.35M | 167.65M | 115.96M | 121.46M |